Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q1 EPS of $0.13, $0.41 worse than the analyst estimate of $0.54. Revenue for the quarter came in at $34.66 million versus the consensus estimate of $71.6 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.